[go: up one dir, main page]

WO2011038110A3 - Methods of treating metabolic disease - Google Patents

Methods of treating metabolic disease Download PDF

Info

Publication number
WO2011038110A3
WO2011038110A3 PCT/US2010/049986 US2010049986W WO2011038110A3 WO 2011038110 A3 WO2011038110 A3 WO 2011038110A3 US 2010049986 W US2010049986 W US 2010049986W WO 2011038110 A3 WO2011038110 A3 WO 2011038110A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
sirt6
metabolic disease
treating metabolic
expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2010/049986
Other languages
French (fr)
Other versions
WO2011038110A2 (en
Inventor
Raul Mostoslavsky
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
General Hospital Corp
Original Assignee
General Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by General Hospital Corp filed Critical General Hospital Corp
Publication of WO2011038110A2 publication Critical patent/WO2011038110A2/en
Publication of WO2011038110A3 publication Critical patent/WO2011038110A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Obesity (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

It has been discovered that SIRT6 functions as a histone H3K9 deacetylase to control the expression of multiple glycolytic genes. Specifically, SIRT6 appears to function as a co-repressor of the transcription factor Hif1?, a critical regulator of nutrient stress responses. This invention relates generally to methods of reducing expression or activity of SIRT6 to reduce or inhibit hyperglycemia or obesity in a subject.
PCT/US2010/049986 2009-09-23 2010-09-23 Methods of treating metabolic disease Ceased WO2011038110A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US24509809P 2009-09-23 2009-09-23
US61/245,098 2009-09-23
US25204409P 2009-10-15 2009-10-15
US61/252,044 2009-10-15

Publications (2)

Publication Number Publication Date
WO2011038110A2 WO2011038110A2 (en) 2011-03-31
WO2011038110A3 true WO2011038110A3 (en) 2011-10-20

Family

ID=43796483

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2010/049986 Ceased WO2011038110A2 (en) 2009-09-23 2010-09-23 Methods of treating metabolic disease

Country Status (1)

Country Link
WO (1) WO2011038110A2 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5883006B2 (en) 2010-09-10 2016-03-09 ニューロントリックス・ソリューションズ・エルエルシーＮｅｕｒｏｎｅｔｒｉｘ Ｓｏｌｕｔｉｏｎｓ， ＬＬＣ Biomarker fusion device and system
WO2013111081A1 (en) 2012-01-24 2013-08-01 Bar-Ilan University Treatment of disease by modulation of sirt6
US9650637B2 (en) 2012-01-24 2017-05-16 Bar-Ilan University Treatment of disease by modulation of SIRT6
EP3777896A1 (en) * 2012-03-15 2021-02-17 Immix Corporation Micelle comprising an inhibitor of nf-kb
EP2906197A1 (en) 2012-10-09 2015-08-19 The Procter & Gamble Company Method of identifying synergistic cosmetic combinations
EP2906946A1 (en) 2012-10-09 2015-08-19 The Procter & Gamble Company Method of identifying or evaluating beneficial actives and compositions containing the same
ITMI20130646A1 (en) * 2013-04-19 2014-10-20 Univ Bologna Alma Mater CHINAZOLINDIONIC COMPOUNDS WITH INHABITING ACTIVITIES ON SIRTUINES
ITMI20130647A1 (en) * 2013-04-19 2014-10-20 Univ Bologna Alma Mater COMPOUNDS WITH INHABITING ACTIVITIES ON SIRTUINES
WO2023091783A1 (en) * 2021-11-22 2023-05-25 H. Lee Moffitt Cancer Center And Research Institute, Inc. Engineered immune cells with reduced sirt6 expression
US20240315237A1 (en) * 2023-02-17 2024-09-26 Abbott Diabetes Care Inc. Methods for single cell analysis of glucose internalization

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050204410A1 (en) * 2004-03-15 2005-09-15 Margaret Karow SIRT6 transgenic non-human animals and assay methods
US20070232528A1 (en) * 2004-04-30 2007-10-04 Hanshermann Franke Formulation comprising histone deacetylase inhibitors
WO2008138943A2 (en) * 2007-05-14 2008-11-20 Universite Libre De Bruxelles Prophylactic and therapeutic use of sirtuin inhibitors in tnf-alpha mediated pathologies

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050204410A1 (en) * 2004-03-15 2005-09-15 Margaret Karow SIRT6 transgenic non-human animals and assay methods
US20070232528A1 (en) * 2004-04-30 2007-10-04 Hanshermann Franke Formulation comprising histone deacetylase inhibitors
WO2008138943A2 (en) * 2007-05-14 2008-11-20 Universite Libre De Bruxelles Prophylactic and therapeutic use of sirtuin inhibitors in tnf-alpha mediated pathologies

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
C. H. WESTPHAL ET AL.: "A therapeutic role for sirtuins in diseases of aging?", TRENDS IN BIOCHEMICAL SCIENCES, vol. 32, no. 12, 2007, pages 555 - 560, XP022355518 *
RAUL MOSTOSLAVSKY ET AL.: "Genomic instability and aging-like phenotype in the absence of mammalian SIRT6.", CELL, vol. 124, no. 2, 2006, pages 315 - 329, XP002430108, DOI: doi:10.1016/j.cell.2005.11.044 *

Also Published As

Publication number Publication date
WO2011038110A2 (en) 2011-03-31

Similar Documents

Publication Publication Date Title
WO2011038110A3 (en) Methods of treating metabolic disease
LTC2137143I2 (en) PLEUROMUTILIN DERIVATIVES FOR THE TREATMENT OF MICROBIAL DISEASES
HK1211231A1 (en) Exendin-4 derivatives
EP2217596B8 (en) Bicyclic heterocycle derivatives and their use as modulators of the activity of gpr119
WO2009089494A3 (en) Pharmaceutical compositions
BRPI0919288A2 (en) combination therapy for treatment of diabetes and related conditions.
IL244668A0 (en) Compositions and formulations for prevention and treatment of diabetes and obesity, and methods of production and use thereof in glucose and caloric control
EP4578500A3 (en) Compositions and methods for improving mitochondrial function and treating neurodegenerative diseases and cognitive disorders
EP3703066B8 (en) Method, system and computer program product for cgm-based prevention of hypoglycemia via hypoglycemia risk assessment
BR112012010261A2 (en) microcannula device, and methods for treating the supracoroidal space of an eye, for treating the posterior region of an eye, and for treating tissues within or adjacent to the supracoroidal space of an eye.
WO2008077092A3 (en) Combined effects of topiramate and ondansetron on alcohol consumption
WO2013186240A3 (en) Exendin-4 peptide analogues
GB201101459D0 (en) Novel compounds and thier effects on fedding behaviour
WO2009068659A3 (en) Novel disease treatment by predicting drug association
WO2010080756A3 (en) Harmine derivatives for reducing body weight
NZ597510A (en) NOVEL ACETYLSALICYLIC ACID SALTS, the salts are 4-trimethylammoniobutanoate, L-carnitine and meldonium
WO2011150007A3 (en) Treatment of methionine sulfoxide reductase a (msra) related diseases by inhibition of natural antisense transcript to msra
BR112013016789A2 (en) treatment of pain associated with displacement of the basal endometrium
ZA201301231B (en) Treatment of l-dopa,dopamine agonist and/or dopamine enhancer induced disorders
WO2010086828A3 (en) Agonist anti-trkb monoclonal antibodies
WO2014068033A3 (en) Animal model for type 2 diabetes and obesity
WO2011136573A3 (en) Yeast hydrolysate having obesity treatment effects and antioxidant activity
WO2010005799A3 (en) Novel acetates of 2-deoxy monosaccharides with anticancer activity
WO2011050008A9 (en) Combination therapy comprising administration of an amylinomimetic and a pyy peptidomimetic for effecting weight loss and for treating obesity and related metabolic conditions and disorders
WO2013033165A3 (en) Compositions, kits and methods for treating obesity, diabetes and hyperglycemia

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10819453

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10819453

Country of ref document: EP

Kind code of ref document: A2